Knight Therapeutics公司已正式向阿根廷和墨西哥的药品监管机构提交了Minjuvi®(Tafasitamab)用于治疗滤泡性淋巴瘤的补充注册申请。这一进展标志着该药物在拓展拉丁美洲市场方面迈出关键一步,为当地患者提供新的治疗选择。
Knight Therapeutics公司已正式向阿根廷和墨西哥的药品监管机构提交了Minjuvi®(Tafasitamab)用于治疗滤泡性淋巴瘤的补充注册申请。这一进展标志着该药物在拓展拉丁美洲市场方面迈出关键一步,为当地患者提供新的治疗选择。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.